Science in Action

This poster reports the efficacy and safety results from the open-label Phase 2 Cohort 1 trial evaluating Vabametkib in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. MET exon 14 skipping is a clinically important therapeutic target in NSCLC, and this study assessed the clinical efficacy and safety profile of Vabametkib in this molecularly defined patient population. The findings provide important Phase 2 clinical evidence supporting the therapeutic potential of Vabametkib as a targeted treatment for patients with MET exon 14 skipping-positive NSCLC.

This poster presents the ongoing Phase 2 Cohort 2 clinical trial evaluating the combination of Vabametkib and Lazertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who developed resistance to first-line third-generation EGFR-TKI therapy through c-MET dysregulation. The study is designed to assess a combination strategy targeting MET amplification and overexpression, one of the most common mechanisms of resistance to third-generation EGFR-TKIs. This important clinical trial aims to establish a novel therapeutic option for overcoming EGFR-TKI resistance and improving treatment outcomes for patients with MET-driven acquired resistance.

This poster presents an innovative therapeutic strategy for inducing the abscopal effect in colorectal cancer through the combination of antibody-conjugated photothermal nanoparticles and the immunocytokine ABN202. ABN202 is a CLDN3-targeted interferon-beta immunocytokine designed to selectively deliver immune-stimulatory activity to CLDN3-expressing tumors. When combined with photothermal therapy, ABN202 not only enhances anti-tumor effects at the locally treated site but also induces systemic immune responses capable of suppressing distant metastatic lesions through the abscopal effect. These preclinical findings demonstrate the potential of this combination approach as a novel immunotherapeutic strategy for the treatment of metastatic colorectal cancer.

This poster presents ABN202, a TROP2-targeted sacituzumab-interferon-beta mutein fusion protein, as a novel therapeutic approach that extends beyond conventional antibody-drug conjugate (ADC) therapies. The study evaluated the anti-tumor efficacy of ABN202 in both ADC-naïve and ADC-refractory cancer models, demonstrating that this immunocytokine fusion protein platform has the potential to overcome the limitations of existing ADCs while providing a sustained therapeutic option even after the development of ADC resistance. These preclinical findings support ABN202 as a promising next-generation targeted immunotherapy with the potential to address unmet medical needs in both treatment-naïve and ADC-resistant cancers.

This poster presents the preclinical evaluation of ABN501, a CLDN3 (Claudin-3)-targeted monoclonal antibody, demonstrating its favorable safety profile, pharmacokinetic properties, and synergistic anti-tumor efficacy. Claudin-3 is a tight junction protein that is overexpressed in a variety of solid tumors, making it an attractive therapeutic target. ABN501 selectively targets CLDN3-expressing tumor cells to inhibit tumor growth and has shown synergistic anti-tumor effects when combined with other therapeutic agents. These findings support the potential of ABN501 as a novel targeted therapy for CLDN3-positive solid tumors, providing a strong rationale for its further clinical development.

This poster establishes proof of concept for BsABN501, a CD3 T cell engager built on the anti-CLDN3 sequence of ABN501. Claudin-3 (CLDN3) contributes to tumor initiation, progression, and metastasis and is overexpressed in multiple solid tumors, including breast, ovarian, and small cell lung cancer. BsABN501 binds CLDN3 on tumor cells while simultaneously engaging CD3 on T cells, thereby triggering T cell-dependent cellular cytotoxicity (TDCC). In vitro assays showed that BsABN501 activates peripheral blood mononuclear cells and induces potent TDCC against CLDN3-positive cancer cell lines. Ongoing work focuses on optimizing the CD3 sequence and the molecular format to further improve efficacy and safety, supporting BsABN501 as a targeted immunotherapeutic for CLDN3-expressing malignancies.

This poster reports the promising antitumor activity of the combination of Vabametkib (ABN401) and lazertinib in patients with advanced non-small cell lung cancer (NSCLC) who developed resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) and harbor MET alterations, including MET amplification and overexpression. The combination strategy simultaneously targets EGFR and MET, one of the principal mechanisms underlying acquired resistance to third-generation EGFR-TKIs, thereby overcoming the limitations of EGFR-targeted monotherapy. The study demonstrates that dual inhibition of EGFR and MET represents a precision medicine approach capable of overcoming treatment resistance and achieving durable antitumor responses in patients with EGFR-mutant, MET-altered NSCLC.

This poster presents a preclinical evaluation of the single-dose toxicity profile of ABN101, a subunit vaccine developed to protect against Staphylococcal Enterotoxin B (SEB), a recognized biological threat agent. Based on a recombinant SEB subunit antigen, ABN101 is being developed as a medical countermeasure for biodefense applications, including preparedness against bioterrorism and other biological emergencies. The study assessed the toxicological safety of the vaccine following a single administration and demonstrated its favorable preclinical safety profile, supporting its further development as a biodefense vaccine. These findings represent an important step toward the clinical translation of ABN101 as a safe and effective countermeasure against SEB-related biological threats.

This poster presents an innovative vaccine delivery platform that combines an enhanced Microneedle Array Patch (eMAP) with low-voltage electroporation to improve the delivery efficiency of the ABN101 DNA vaccine. The technology is designed to overcome the limitations of conventional intramuscular injection by enabling intradermal delivery, thereby enhancing DNA vaccine uptake, immunogenicity, and bioavailability. By integrating minimally invasive microneedle technology with low-voltage electroporation, the platform offers a rapid, efficient, and user-friendly approach to DNA vaccine administration. This study demonstrates the potential of the eMAP platform as a next-generation vaccine delivery technology capable of supporting rapid and effective immunization for biodefense and emerging infectious disease preparedness.

This poster presents the development of various formulations of ABN101, an interferon-beta mutein, as an immediate medical countermeasure against emerging viral threats. ABN101 is an engineered interferon-beta mutein with enhanced stability and antiviral efficacy, designed as a host-directed therapeutic capable of providing broad-spectrum antiviral protection against newly emerging infectious diseases. By optimizing multiple formulations and routes of administration, the program aims to enable rapid deployment and effective treatment during pandemics, biological emergencies, and biodefense scenarios. These findings demonstrate the potential of ABN101 as a versatile medical countermeasure platform that can provide timely and effective responses to future biological threats.

This poster introduces ABN202, a potent antibody–cytokine fusion protein platform developed for the treatment of a broad range of solid tumors. ABN202 combines tumor antigen-targeting antibodies with an enhanced interferon-beta mutein to enable selective cytokine delivery to the tumor microenvironment, thereby maximizing anti-tumor immune responses while minimizing systemic toxicity. The modular platform is designed to accommodate different tumor-specific antigens, allowing the development of customized therapeutics for multiple cancer types. These preclinical findings demonstrate the potential of the ABN202 platform as a next-generation targeted immunotherapy capable of overcoming key limitations of conventional immunotherapies and expanding treatment opportunities across diverse solid tumors.

This poster presents a biomarker study evaluating the concordance between MET-positive circulating tumor cells (CTCs) and disease progression in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The study investigated the clinical utility of liquid biopsy-based detection of MET-positive CTCs as a non-invasive biomarker for the early prediction and monitoring of MET amplification-mediated resistance during EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. The strong correlation observed between the presence of MET-positive CTCs and disease progression supports their potential use in guiding personalized treatment strategies and determining the optimal timing for MET-targeted therapy. These findings provide important translational evidence for integrating CTC-based biomarker analysis into the clinical management of patients with EGFR-mutated NSCLC.

This poster presents a preclinical study evaluating ABN202, a potent antibody–cytokine fusion protein developed for the treatment of Trop-2-positive solid tumors. ABN202 combines a Trop-2-targeting antibody with an enhanced interferon-beta mutein, enabling selective binding to Trop-2-overexpressing tumor cells and targeted delivery of interferon-beta to the tumor microenvironment. This localized cytokine delivery is designed to maximize anti-tumor immune activation while minimizing systemic toxicity. Unlike conventional Trop-2-targeted antibody–drug conjugates (ADCs), ABN202 employs a distinct mechanism of action based on immune modulation, suggesting the potential to overcome resistance to existing ADC therapies. These findings support ABN202 as a promising next-generation targeted immunotherapy for patients with Trop-2-positive solid tumors.

This poster presents a preclinical study evaluating a trispecific immunocytokine, ABN202, an anti-VISTA × MSLN bispecific antibody–interferon-beta mutein fusion protein, which demonstrated potent therapeutic efficacy against epithelial mesothelioma. This innovative therapeutic is designed with a triple mechanism of action: it selectively targets mesothelin (MSLN) expressed on tumor cells, blocks the immune checkpoint molecule VISTA to relieve immunosuppression, and delivers an enhanced interferon-beta mutein directly to the tumor microenvironment to stimulate anti-tumor immunity. By combining targeted tumor recognition, immune checkpoint inhibition, and localized cytokine activation, ABN202 induced robust anti-tumor immune responses even in immunologically "cold" tumors such as mesothelioma. These findings support the potential of ABN202 as a next-generation multi-targeted immunotherapy platform capable of overcoming the limitations of conventional single-target therapeutic approaches.

This poster presents a preclinical study evaluating ABN202, an anti-EGFR antibody–interferon-beta mutein fusion protein, which demonstrated potent anti-tumor activity against non-small cell lung cancer (NSCLC) regardless of EGFR mutation status through both direct cytotoxicity and indirect immune activation. ABN202 employs a dual mechanism of action by selectively binding to EGFR-expressing tumor cells to induce direct tumor cell death while simultaneously activating anti-tumor immune responses within the tumor microenvironment through an enhanced interferon-beta mutein. These findings suggest that ABN202 has the potential to serve as a next-generation EGFR-targeted immunotherapy with broad applicability across EGFR-expressing lung cancers, overcoming the limitations of conventional EGFR tyrosine kinase inhibitors (TKIs) and providing a promising therapeutic option irrespective of EGFR mutation status.

This poster presents preclinical findings demonstrating the potential of ABN501, a novel antibody targeting claudin-3, as a new therapeutic option for small cell lung cancer (SCLC). Claudin-3, a tight junction protein, is overexpressed in a variety of malignant tumors, with particularly high expression in SCLC. By selectively targeting claudin-3, ABN501 inhibited tumor growth and metastasis, highlighting its potential to address the significant unmet medical need in SCLC, where current treatment options remain limited. These findings support the development of ABN501 as a promising targeted therapy for patients with this aggressive malignancy.

ABN101 is an interferon-beta variant with an additional glycosylation chain designed to improve stability, solubility, pharmacokinetic (PK) properties, and biological activity. It has been developed as a dry powder inhalation formulation for targeted pulmonary delivery to treat respiratory viral infections. Using a spray-drying process, spherical ABN101 dry powder particles with a median diameter of approximately 2.5 μm were successfully manufactured while retaining 80–90% of biological activity (700 MIU/mg), demonstrating its potential as a broad-spectrum antiviral therapeutic for respiratory diseases.

This presentation highlights the efficacy and safety outcomes of ABN401 in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. The abstract was published in Molecular Cancer Therapeutics, Vol. 22, 12_Supplement, and was selected for the SHOWCASE Poster Session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. It represents an important presentation of interim results from ABION's global Phase 2 clinical trial, further supporting the clinical potential of ABN401 as a novel c-MET tyrosine kinase inhibitor.

This poster presents a clinically relevant subgroup analysis evaluating the efficacy and safety of ABN401 (Vabametkib) in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. The study was published in Molecular Cancer Therapeutics, Vol. 22, 12_Supplement, and highlights interim results from ABION's global Phase 2 clinical trial, providing important clinical evidence supporting the therapeutic potential of ABN401 in this molecularly defined patient population.

This poster describes ABN101, a novel dry powder inhaler developed as a broad-spectrum antiviral therapy for the prevention and treatment of global respiratory viral pandemics. The study was published in the American Journal of Respiratory and Critical Care Medicine, Vol. 207, Supplement_1. ABN101 represents a novel dry powder inhalation formulation designed to provide broad-spectrum antiviral activity against respiratory viruses, supporting its potential as an effective countermeasure for future pandemic preparedness.

This poster presents the potent anti-cancer activity of ABN501, a novel anti-claudin-3 antibody, demonstrated in both in vitro and in vivo preclinical models. The study was published in Cancer Research, Vol. 83, 7_Supplement, providing preclinical evidence supporting the therapeutic potential of ABN501 as a targeted antibody therapy for claudin-3-expressing cancers.

This poster describes the synergistic anti-tumor activity of ABN401 in combination with a KRAS inhibitor in a c-MET-altered KRASG12C non-small cell lung cancer (NSCLC) model. The study was published in Cancer Research, Vol. 83, 7_Supplement, and provides preclinical evidence supporting the therapeutic potential of combining c-MET and KRAS inhibition to enhance anti-tumor efficacy in molecularly defined NSCLC.

This poster presents preclinical findings demonstrating the robust anti-tumor efficacy of ABN401 in orthotopic patient-derived xenograft (PDX) models of MET-driven non-small cell lung cancer (NSCLC) brain metastases. The study was published in Cancer Research, Vol. 83, 7_Supplement. As brain metastases remain a major clinical challenge in patients with NSCLC, these findings provide important evidence supporting ABN401's ability to penetrate the blood-brain barrier and its therapeutic potential for the treatment of brain metastases.

This abstract presents the results of the pilot expansion study evaluating ABN401 in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. The study was published in the Journal of Clinical Oncology, Vol. 41, 16_suppl, and was presented as a Publication Only (e-Poster), representing an important clinical update on the efficacy and safety of ABN401 in this molecularly defined patient population.

This abstract describes the development of ABN501, a Claudin-3-specific human monoclonal antibody, as a therapeutic anti-tumor agent. The study was published in Cancer Research, Vol. 82, 12_Supplement, and was selected as a Proffered Abstract for poster presentation, highlighting its scientific significance.

This poster presents the results of the first-in-human (FIH) Phase 1 clinical trial of ABN401, representing a significant clinical development milestone for ABION. The study established the initial safety, tolerability, pharmacokinetic profile, and recommended dose for subsequent clinical development.

This poster presented a Trial in Progress (TiP) describing a Phase I–II multicenter, open-label, dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors, as well as a dose-expansion cohort in patients with non-small cell lung cancer (NSCLC) harboring c-MET dysregulation. The abstract was published in Annals of Oncology in September 2022.

This poster demonstrated that MET-enriched circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are significant biomarkers for predicting disease progression in HR-positive, HER2-negative metastatic breast cancer. The study, published in Annals of Oncology in September 2022, represents an important biomarker investigation involving ABION.

This poster presented important preclinical evidence supporting the combination strategy of ABN401 for overcoming resistance to third-generation EGFR-TKIs. The abstract was published in Annals of Oncology in September 2022. The study proposed a therapeutic strategy targeting MET amplification, one of the key mechanisms underlying resistance to EGFR-TKI therapy.

This poster presented a Trial in Progress (TPS) describing a Phase 1–2 multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors. The abstract was published in Journal of Clinical Oncology, Volume 39, Issue 15 Supplement. It introduced the initial clinical development plan for the first-in-human study of ABN401.

This poster reported that MET-enriched circulating tumor cells (CTCs) and cell-free DNA (cfDNA) concentration are significant independent predictors of disease progression in patients with HR-positive, HER2-negative metastatic breast cancer. The presentation highlighted biomarker research supporting the clinical development of ABN401.

This poster reported a preclinical study demonstrating that the combination of ABN401 and a third-generation EGFR-TKI is effective against MET-amplified, EGFR-mutant non-small cell lung cancer (NSCLC) with acquired resistance to third-generation EGFR-TKIs. The abstract was published in Annals of Oncology, Volume 33, Supplement 7.

This poster presented the results of a Phase I dose-escalation study evaluating the safety and clinical activity of the c-MET inhibitor ABN401 in patients with advanced solid tumors. The abstract was published in Annals of Oncology, Volume 32, Supplement 5. It represents the first report of clinical trial results from the first-in-human study of ABN401.

This paper investigated the determination of the solubility of a c-Met inhibitor in solvent mixtures and the mathematical modeling for the development of a nanosuspension formulation. To address the poor aqueous solubility of the c-Met inhibitor, the study measured its solubility in various solvent systems and developed an optimized nanosuspension formulation through mathematical modeling, thereby improving its bioavailability and enhancing its potential for clinical application.

This paper evaluated the therapeutic efficacy of ABN401, a highly potent and selective MET inhibitor, in MET-dependent cancers based on diagnostic biomarker testing. The study demonstrated the antitumor activity of ABN401 across various cancer types with MET amplification or overexpression and established the clinical utility of MET biomarker-based patient selection strategies, providing important preclinical evidence for the development of precision medicine-based MET-targeted therapies.

This paper is a preclinical study evaluating the development of a novel c-Met inhibitor and its combination antitumor effects in c-Met-amplified non-small cell lung cancer (NSCLC). The study verified the antitumor activity of both monotherapy and combination therapy in c-Met-amplified NSCLC models and demonstrated the potential for developing new therapeutic strategies for c-Met-amplified lung cancer through synergistic effects with other targeted therapies.